Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Agenus (AGEN) stock in plain English

Free brief · no signupStart here
AGENPublished Nov 19, 2026
Agenus Inc
Healthcare · Biotechnology
Develops antibody-based immunotherapies and adjuvant components for cancer vaccines.
Assets:
Botensilimab candidateLate-stage Fc-enhanced immunotherapy tested in solid tumor clinical trials
California manufacturingInternal antibody discovery and pilot manufacturing plant in Emeryville
Stimulon platformProprietary QS-21 vaccine adjuvant licensed to external pharmaceutical makers
Locked assetIn the full report
Checked Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

82
OPS ScoreOperating finances
Latest quote
-4.06%$6.14
$277.82M
8.5×
$134.21M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 19, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was AGEN. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Agenus (AGEN) do?

Agenus Inc (AGEN) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Develops antibody-based immunotherapies and adjuvant components for cancer vaccines. Develops and manufactures its own immune-activating antibody therapies and vaccine adjuvants for cancer treatment. It is worth $277.82M on the market and sold $134.21M over the last year.

Market cap
$277.82M
P/E ratio
8.5×
Annual sales
$134.21M
Sector
Healthcare
Industry
Biotechnology
Brief updated
Nov 19, 2026

Brands and businesses behind AGEN

  • Stimulon: A vaccine adjuvant technology that generates licensing revenue and royalty payments from partner pharmaceutical companies.

AGEN’s flags, in plain English

Each flag is a number from Agenus’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 19, 2026.

Wide Gross Margin

Gross margin of 98.4% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Capital Works Hard

Earns 62.8% a year on the money it invests in the business. The money in the business, from shareholders and lenders together, earns a strong return. That points to a company that picks its investments well.

Earnings Jumping

Profits up 133.2% this year. Profit per share is growing fast this year. One year does not make a trend, so check whether sales grew too.

Runway Is Short

This year's bills are bigger than the cash and assets on hand to pay them. At its current rate of spending, its cash on hand covers only a limited stretch.

2 more green flags and 2 more risk notes open with the free trial. Try it free for 7 days.

Questions about AGEN

How big is Agenus?

Agenus’ market cap is $277.82M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $134.21M: what customers paid the company over the last year, before any costs.

What is AGEN’s P/E ratio?

AGEN’s P/E ratio is 8.5×. Investors pay about 8.5 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with AGEN?

The business operates at a continuous net loss and relies heavily on external financing to fund clinical programs. That is one risk on Agenus’ card. Its first risk flag is Runway Is Short, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Agenus’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. AGEN’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card